The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

URGENT BC Patient and Caregiver Input Request: Vosevi

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Check out the background information in links below to see the results that have been achieved in clinical trials to date. Gilead’s “SOF-VEL-VOX” combo is pan-genotypic (works for all genotypes). One pill

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

The Week in Review: July 14 – July 21, 2017

Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....

The Week in Review: June 16 – June 30, 2017

Friday, June 30, 2017 News Recap Well if you blinked you didn’t miss it because there was no Weekly Bull last week.  Just felt that it was best not to bother you all for not much. But now we have quite a few items to share. Important Warning: Please please be aware of computer safety.  There are all kinds of viruses out there that will destroy your computer and trash your files and work.  If it happened to banks and even Merck it can happen to you...

CHMP Backs Two Pan-Genotypic Antivirals for Hep C

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of two new drugs, Maviret and Vosevi, for the treatment of chronic hepatitis C virus (HCV) infection in adults. Maviret (AbbVie Ltd), administered once daily as three oral tablets, contains the NS3/4A protease inhibitor glecaprevir (100 mg) and the NS5A inhibitor pibrentasvir (40 mg). Vosevi (Gilead Sciences) is a once-daily single